EUCTR2019-004998-34-GB进行中（未招募）1 期
A Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate Pharmacodynamics, Pharmacokinetics, and Safety of BLD-2660 Administered Orally in Subjects with Idiopathic Pulmonary Fibrosis - B-2660-203
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •To be eligible for inclusion into this study, each subject must fulfil the following inclusion criteria within 20 days prior to Randomisation on Day 1.
- •Age and Gender
- •1. Male subjects 45 years of age and over, or female subjects 50 years of age and over, at the time of signing the informed consent.
- •Diagnosis and disease characteristics
- •2. Subjects with diagnosis of IPF as defined by the American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of Idiopathic Interstitial Pneumonia (Raghu, 2018).
- •3. FVC >45% predicted and diffusing capacity of the lung for carbon monoxide (DLCO) >30% predicted.
- •4. Alanine aminotransferase (ALT) within normal limits (WNL).
- •5. Aspartate aminotransferase (AST) and alkaline phosphatase (ALP) =1.2 × upper limit of normal (ULN).
- •6. Total bilirubin =ULN (isolated bilirubinemia =2× ULN is acceptable if direct bilirubin to total bilirubin ratio <0.35).
- •7. Body mass index (BMI) up to 35 kg/m2 inclusive.
- •Reproductive Considerations
- •Contraception use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
- •8. All subjects (male or female) who are of childbearing potential must agree to use highly effective contraception during the study, including:
- •intrauterine device (IUD);
- •bilateral tubal occlusion;
- •vasectomised partner a;
- •sexual abstinence b.
- •Notes: a Vasectomised partner is a highly effective birth control method provided that the partner is the sole sexual partner of the women of childbearing potential (WOCBP) trial participant and that the vasectomised partner has received medical assessment of the surgical success.
- •b Sexual abstinence is defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the subject.
- •Hormonal contraceptives (HC) are restricted during the study.
- •9. Male subjects and female partners of male subjects must continue to use highly effective contraception, as listed in Inclusion criterion 8, for 90 days after the last dose of study drug. Male subjects must agree not to donate sperm for 90 days after last dose of study drug.
- •10. Female subjects and male partners of female subjects must continue to use highly effective contraception, as listed in Inclusion criterion 8, for 60 days after the last dose of study drug. Female subjects should not donate oocytes during this time.
- •11. Female subjects of childbearing potential must have a negative serum pregnancy test at Screening and a negative urine pregnancy test on Day (-1). WOCBP must agree to undergo pregnancy testing at regular intervals throughout the study.
- •12. Female subjects not of childbearing potential as defined by being postmenopausal (with cessation of regular menstrual periods for at least 1 year), confirmed by follicle stimulating hormone (FSH) level, or be surgically sterile.
- •Informed Consent
- •13. Subjects must provide signed informed consent prior to study entry and have the ability and willingness to attend and comply with the necessary visits at the study site.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 40
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of sub
排除标准
- •To be eligible for inclusion into this study, each subject must violate none of the following exclusion criteria within 20 days prior to Randomisation on Day 1:
- •Medical Conditions
- •1. Recent (less than 6 weeks) significant wound (in the opinion of the Investigator), or presence of an ongoing non-healing skin wound or ulcer.
- •2. Presence of any underlying physical or psychological medical condition that, in the opinion of the Investigator, would make it unlikely that the subject will complete the study per protocol.
- •3. Active infection (diagnosed or suspected) or history of recurrent infections, including but is not limited to, bronchitis, pneumonia, sinusitis, urinary tract infection, cellulitis or chronic ongoing infectious disease within 4 weeks prior to first dose of study drug.
- •Note: Rescreening will be permitted after 28 days if an infection leads to screening failure.
- •4. Active malignancy and/or history of malignancy in the past 5 years, except for non-melanoma skin cancer, carcinoma in situ of the breast that has been successfully treated, carcinoma in situ of the cervix that has been successfully treated, early stage, untreated prostate cancer, or prostate cancer with completion of treatment >2 years prior to Screening.
- •5. Extensive chronic obstructive pulmonary disease (where extent of emphysema >extent of fibrosis on computerised tomography (CT) scan or FEV1: FVC ratio <0.65).
- •6. Other explanation for lung fibrosis, including but not limited to radiation, sarcoidosis, bronchiolitis obliterans organizing pneumonia, collagen vascular disease, hypersensitivity pneumonitis, etc.
- •7. IPF exacerbation within last 60 days.
- •8. A history or current evidence of any medical condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subjects’ participation for the full duration of the study, or is not in the best interest of the subjects to participate, in the opinion of the Investigator.
- •Diagnostic Assessments
- •9. Positivity for Human Immunodeficiency Virus (HIV) antibody (HIV-1 and/or HIV-2) and/or HIV-1 p24 antigen.
- •10. Positivity for Hepatitis C virus antibody (HCV Ab or anti-HCV) and/or Hepatitis B surface antigen (HBsAg).
- •11. Absolute neutrophil count <1700/µL.
- •12. Significant hypoxia, requiring >2 L/min oxygen to maintain a resting oxygen saturation >89%.
- •13. Poor exercise tolerance.
- •14. Serum troponin I level >ULN.
- •Prior/Concomitant Therapy
- •15. Use of anticoagulants that prolong Prothrombin time (PT)/ International normalised ratio (INR).
- •16. Use of anticoagulants within 2 days of Day (-1) (bronchoscopy)
- •Note: The subjects who cannot discontinue the anticoagulants within 2 days of Day (-1) bronchoscopy will be excluded.
- •17. Treatment with any anti-fibrotic therapy (pirfenidone or nintedanib) within 30 days of Screening.
- •18. Immunosuppressive therapy within 3 months prior to first dose of study drug unless for non-IPF indication).
- •19. Use of oral steroids >10 mg/day (or prednisolone equivalent).
- •Note: If the subject is on steroid dose equivalent to 10 mg/day prednisone or more, the Investigator may decide if the tapering down to the dose of 10 mg/day prednisone is possible and safe.
- •20. Start of new biologic or change in biologic dose within 24 weeks prior to Day 1.
- •21. Cyclophosphamide within 6 months prior to the first dose of study drug (unless for other indication).
- •Prior/Concurrent Clinical Study Experience
- •22. Administration of another investigational product, investigation
研究者
相似试验
进行中（未招募）
不适用
A study in patients with chondrosarcoma comparing IPI-926 to placeboEUCTR2010-024518-74-ESInfinity Pharmaceuticals, Inc169
进行中（未招募）
不适用
A Phase 2, Double-Blind, Placebo-Controlled Study of Uro-Vaxom® for the Management of Uncomplicated Recurrent Urinary Tract Infections - A Study of Two Doses of Uro-Vaxom® for the Management of Recurrent Urinary Tract Infectionsncomplicated recurrent urinary tract infectionsMedDRA version: 9.1Level: LLTClassification code 10038140Term: Recurrent urinary tract infectionEUCTR2008-001784-11-DEAlita Pharmaceuticals, Inc.420
进行中（未招募）
1 期
A study in patients with chondrosarcoma comparing IPI-926 to placeboMetastatic or Locally Advanced ChondrosarcomaMedDRA version: 14.1Level: PTClassification code 10008734Term: ChondrosarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-024518-74-GBInfinity Pharmaceuticals, Inc105
进行中（未招募）
不适用
A study in patients with chondrosarcoma comparing IPI-926 to placeboMetastatic or Locally Advanced ChondrosarcomaMedDRA version: 14.1Level: PTClassification code 10008734Term: ChondrosarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-024518-74-NLInfinity Pharmaceuticals, Inc140
进行中（未招募）
不适用
A study in patients with chondrosarcoma comparing IPI-926 to placeboMetastatic or Locally Advanced ChondrosarcomaMedDRA version: 14.0Level: PTClassification code 10008734Term: ChondrosarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-024518-74-DEInfinity Pharmaceuticals, Inc140